Ritter Pharmaceuticals | Therapeutic Treatments for Gastrointestinal Diseases

Press Releases / News

2013

April – Andrew Ritter Named Finalist in LA Business Journal’s Annual Healthcare Leadership Awards

April - Patient Survey: More than 80% Forced to Change Lifestyles Due to Lactose Intolerance

March – Ritter Pharmaceuticals Encouraged by Meeting with FDA

February - Ritter Pharmaceuticals Names Larry Good, M.D. Chief Medical Officer

January - Survey: 75% of People with Lactose Intolerance Avoid Dairy Food

January - Lactose Intolerance: Major Unmet Medical Need

2012

July – Ritter Pharmaceuticals Appoints Michael Step to the Board of Directors

May – Ritter Pharmaceuticals Presents Its Phase 2 Study of RP-G28 at Digestive Disease Week 2012

February - Ritter Pharmaceuticals’ Abstract on RP-G28′s Phase 2 Trial Selected for Oral Presentation at Digestive Disease Week 2012

January – Ritter Pharmaceuticals’ RP-G28 Improves Lactose Intolerance Symptoms and Lactose Digestion in Phase 2 Trial

2011

December – Ritter Pharmaceuticals Appoints Robert H. Tidwell as Chief Business Officer

November – Ritter Pharmaceuticals Completes Phase 2 Trial for Lactose Intolerance

June – Ritter Pharmaceuticals, Inc. Announces First Patient Enrollment in its Phase 2 Clinical Study of RP-G28 for the Treatment of Lactose Intolerance

2010

November – Ritter Pharmaceuticals, Inc. Awarded a Grant under the U.S. Qualified Therapeutic Discovery Project Program

October – Ritter Pharmaceuticals, Inc. Wins Top Awards at Venture Capital Investment Competition

October – Ritter Pharmaceuticals Wins 2010 San Diego Quick Pitch Competition

June – Ritter Pharmaceuticals, Inc. Receives FDA IND Approval For Lactose Intolerance Treatment

February – Ritter Pharmaceuticals, Inc. to Discuss Lactose Intolerance and Associated Health Risks at NIH Conference

2009

September – Ritter Pharmaceuticals’ CEO, Andrew Ritter to Present at the 11th Annual SoCalBio Investor Conference

September – Ritter Pharmaceuticals, Inc. hires Dr. Howard Foyt as Exec VP, Development & Chief Medical Officer